Literature DB >> 19835569

Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs.

G D Kolovou1, K K Anagnostopoulou, P M Kostakou, D P Mikhailidis.   

Abstract

Cholesterol ester transfer protein (CETP) plays a significant role in high density lipoprotein (HDL) metabolism and reverse cholesterol transport (RCT). A reduction in CETP activity leads to an increase in HDL-cholesterol levels. However, the relationship between reduced CETP function and atherosclerosis is complex and confusing. In the hypertriglyceridemic state, CETP is highly expressed and RCT leads to the formation of small dense low density lipoprotein (LDL) and small dense HDL, both of which are involved in the progression of atherosclerosis. Significant associations of the B1B1 genotype with higher plasma CETP concentration and/or CETP activity and lower HDL cholesterol were reported in several, but not all, studies. The magnitude of postprandial lipemia is also associated with plasma CETP concentration and lipoprotein content and size. Several conditions such as metabolic syndrome, hypertension, insulin resistance, obesity and familial hypercholesterolaemia are characterized by a more pronounced postprandial hypertriglyceridemia and delayed TG clearance than normal states. Thus, CETP is considered as a candidate target for drug therapy. A number of synthetic CETP inhibitors (CGS25159 and JTT-705) were evaluated in animals with satisfactory results. In humans, two CETP inhibitors were evaluated, JTT-705 and torcetrapib, leading to HDL increase. However, torcetrapib administration was associated with an increase in blood pressure and other "off-target" effects. It is also not clear whether the HDL produced during treatment with torcetrapib is bioactive (i.e. an "on target" undesirable action). In the current review, CETP function regarding lipid metabolism (in fasting and fed states) from human and animal studies as well as the current knowledge on CETP inhibitors are discussed. We also discuss gender influence on the action of hypolipidemic drugs and their effect on CETP mass and activity, as well as on the lipid profile.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19835569     DOI: 10.2174/092986709789712853

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

1.  Hepatitis C virus G1b infection decreases the number of small low-density lipoprotein particles.

Authors:  Chika Kinoshita; Tomohisa Nagano; Nobuyoshi Seki; Yoichi Tomita; Tomonori Sugita; Yuta Aida; Munenori Itagaki; Kenichi Satoh; Satoshi Sutoh; Hiroshi Abe; Akihito Tsubota; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

2.  High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship.

Authors:  Michael S Kostapanos; Moses S Elisaf
Journal:  World J Exp Med       Date:  2014-02-20

3.  Hypertriglyceridemia is a major factor associated with elevated levels of small dense LDL cholesterol in patients with metabolic syndrome.

Authors:  Yonggeun Cho; Sang Guk Lee; Sun Ha Jee; Jeong Ho Kim
Journal:  Ann Lab Med       Date:  2015-11       Impact factor: 3.464

4.  Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin.

Authors:  Genovefa Kolovou; Georgia Ragia; Vana Kolovou; Constantinos Mihas; Niki Katsiki; Ioannis Vasiliadis; Sophie Mavrogeni; Vassiliki Vartela; Anna Tavridou; Vangelis G Manolopoulos
Journal:  Open Cardiovasc Med J       Date:  2014-02-07

Review 5.  We are ageing.

Authors:  Genovefa D Kolovou; Vana Kolovou; Sophie Mavrogeni
Journal:  Biomed Res Int       Date:  2014-06-22       Impact factor: 3.411

6.  Biomarkers and Gene Polymorphisms in Members of Long- and Short-lived Families: A Longevity Study.

Authors:  Vana Kolovou; Olga Diakoumakou; Athanasia K Papazafiropoulou; Niki Katsiki; Elisabeth Fragopoulou; Ioannis Vasiliadis; Dimitris Degiannis; Leonidas Duntas; Smaragdi Antonopoulou; Genovefa Kolovou
Journal:  Open Cardiovasc Med J       Date:  2018-07-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.